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Introduction
Biologic therapy is increasingly prescribed in rheumato-
logic disorders. Juvenile dermatomyositis (JDM), the
most common inflammatory myopathy in children, can
be challenging to manage in a subset of patients. There
are multiple reports of cytokine involvement in JDM.
There is a paucity of information regarding the use of
biologics for JDM among pediatric rheumatology practi-
tioners, and only one clinical trial investigating a biolo-
gic in JDM.
Objectives
The purpose of the study is to examine pediatric rheu-
matology (PR) experience in North America and Canada
with biologic therapy in children with JDM.
Methods
The Childhood Arthritis and Rheumatology Research
Alliance JDM Subcommittee on Biologics developed a
15-question on-line survey. Of the 231 pediatric rheu-
matology practitioners contacted, 105 (45%) participated
between 2/17-3/20/2012.
Results
Over half (57%) of the respondents currently managed
1-10 patients with JDM; 10% of respondents reported
≥20 patients with JDM in their practice. Sixty-one per-
cent of respondents had used biologics in patients with
JDM, with 32%, 5%, and 4% prescribing rituximab, eta-
nercept and infliximab, respectively; 17% had prescribed
more than one biologic. The majority of respondents
(89%) had used biologics in combination with other
therapies, while 11% had used biologics as monotherapy
in JDM. The biologics used by the respondents were,
rituximab, infliximab, etanercept and anakinra and aba-
tacept. Among the respondents that used biologics,
uncontrolled disease was the primary rationale for pre-
scribing this medication. Over half of respondents used
biologics after the patients failed other therapies; 11% of
respondents used biologics for systemic (internal organ)
involvement and 15% had used biologics for severe
ulcerative disease. Seventy-three percent of respondents
that used biologics noted improvement, while 10%
reported worsening disease. Over half (53%) of respon-
dents that used biologics noted improvement in calcino-
sis, while 64% reported side effects (common and
uncommon). Among the respondents that had not used
biologics (39%) in JDM, 88% would use this therapy if
the opportunity arose; nearly half (47%) of these respon-
dents had not used biologics because of uncertainty
regarding effectiveness in JDM. Seventy percent of prac-
titioners recommended that biologics be formally stu-
died in patients with JDM; 24% of respondents were
unsure and 6% felt biologics should not be studied in
patients with JDM.
Conclusion
Several PR have used biologics in the management of
pediatric patients with JDM. Among respondants that
have not used biologics in this patient population, most
would be interested in prescribing biologics. This survey
supports the rationale for considering clinical trials and
consensus protocols to elucidate the safety and effective-
ness of biologics in children with JDM. Further informa-
tion will be gathered by the CARRA JDM Subcommittee
on Biologics through second survey to prioritize specific
medications for investigation.
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